Cellectis
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Cellectis and buy or sell other stocks, ETFs, and their options commission-free!About CLLS
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J.
CEOAndré Choulika
CEOAndré Choulika
Employees229
Employees229
HeadquartersParis, Ile-de-France
HeadquartersParis, Ile-de-France
Founded2000
Founded2000
Employees229
Employees229
CLLS Key Statistics
Market cap312.32M
Market cap312.32M
Price-Earnings ratio-6.31
Price-Earnings ratio-6.31
Dividend yield—
Dividend yield—
Average volume48.79K
Average volume48.79K
High today$4.35
High today$4.35
Low today$3.95
Low today$3.95
Open price$4.29
Open price$4.29
Volume14.41K
Volume14.41K
52 Week high$5.48
52 Week high$5.48
52 Week low$1.33
52 Week low$1.33
CLLS News
TipRanks 3d
Cellectis Highlights Positive Pivotal Interim Data for Allogeneic CAR-T Partnered Cema-celUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
TipRanks 3d
Cellectis highlights Allogene ALPHA3 trial data, potential milestone paymentsCellectis (CLLS) highlighted the interim futility analysis announced by Allogene Therapeutics (ALLO) from Allogene’s sponsored pivotal ALPHA3 trial evaluating c...
Analyst ratings
86%
of 7 ratingsBuy
85.7%
Hold
14.3%
Sell
0%
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.